Continued volatility in the equity capital markets has revived what was thought to be a zombie after 2022 – the SPAC. There is an old investment banking mantra that they can do an IPO in a down market or an up market, but not...more
It’s never too early to prepare an exit strategy, whether that exit is through an M&A, IPO or additional private financing. Albert Vanderlaan, Justin Yi and Samir Bakhru discuss the need for good corporate hygiene, process...more
This report series examines quarterly trends in life sciences venture investment. Key findings for Q3 2023 include:
Life sciences VC deal value in Q3 2023 totaled $7.7 billion, representing an uptick from last quarter...more
This report series examines quarterly trends in life sciences venture investment. Key findings for Q4 2022 include:
• Deal value reached $7.1 billion in Q4 across 392 deals, bringing the 2022 annual total to $38.0 billion...more
This edition of Orrick’s life sciences publication series breaks down the key drivers of venture investment in the life sciences industry, which is on track to set all-time records this year. Key findings include: • With...more